Week in Review: Shanghai's I-Mab Plans $100 Million NASDAQ IPO on January 16

Deals and Financings • I-Mab of Shanghai announced the terms for its $100 million NASDAQ IPO at a market value of $750 million and announced it has dosed the first patient in a China Phase II trial of a CD38 antibody for multiple myeloma; • Beijing's BeiGene formed a $132 million collaboration with Leap Therapeutics of the US for Asia rights to Leap's DKK1 antibody, which BeiGene intends to test with its recently approved PD-1 drug; • Suzhou's CF PharmaTech, a company focused on providing high-quality and affordable inhalation products globally, raised $90 million in a Series E funding; • MyGene Diagnostics of Guangzhou completed a $14 million Series B round to provide second-gen high throughput screening for cancer clinical diagnostics and treatment guidelines; • Xuanzhu (HK) Biopharma acquired greater China rights to Zemdri, a novel anti-infective, from Achaogen of the US for $4.5 million; Trials and Approvals • BeiGene of Beijing received China approval to market its anti-PD-1 antibody to treat classical Hodgkin’s lymphoma, the first BeiGene drug approved in China; • Clover Biopharma of Chengdu dosed the first patient in a China Phase III trial of SCB-808, an Enbrel® biosimilar, for patients with rheumatic diseases; Government and Regulatory • Jiankui He, the Shenzhen scientist who used CRISPR-Cas9 gene editing to alter the embryos of seven IVF patients, was sentenced to three years in prison and a fine of $430,000 for conducting an experimental test without approval. Stock Symbols: (NSDQ: BGNE; HK: 06160) (NSDQ: LPTX) Share this with colleagues: // //